ANG II enhances contractile responses via PI3-kinase p110δ pathway in aortas from diabetic rats with systemic hyperinsulinemia

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 291, Issue 2, 2006, Pages

  Kobayashi, Tsuneo ^a   Hayashi, Yuko ^a   Taguchi, Kumiko ^a   Matsumoto, Takayuki ^a   Kamata, Katsuo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Contraction; Diabetes; Phosphatidylinositol 3 kinase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ENALAPRIL; LOSARTAN; PROTEIN P110; PROTEIN P85;

ANIMAL MODEL; ARTICLE; BLOOD VESSEL REACTIVITY; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HEART MUSCLE CONTRACTILITY; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA, THORACIC; BLOOD GLUCOSE; BLOOD PRESSURE; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; HYPERINSULINISM; INSULIN; ISOMETRIC CONTRACTION; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL CONTRACTION; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 33746806220     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01349.2005     Document Type: Article

References (40)

1. Anai M, Funaki M, Ogihara T, Terasaki J, Inukai K, Katagiri H, Fukushima Y, Yazaki Y, Kikuchi M, Oka Y, and Asano T. Altered expression levels and impaired steps in the pathway to phosphatidylinositol 3-kinase activation via insulin receptor substrates 1 and 2 in Zucker fatty rats. Diabetes 47: 13-23, 1998.
2. Barbour LA, Shao J, Qiao L, Leitner W, Anderson M, Friedman JE, and Draznin B. Human placental growth hormone increases expression of the p85 regulatory unit of phosphatidylinositol 3-kinase and triggers severe insulin resistance in skeletal muscle. Endocrinology 145: 1144-1150, 2004.
3. Budzyn K, Marley PD, and Sobey CG. Opposing roles of endothelial and smooth muscle phosphatidylinositol 3-kinase in vasoconstriction: effects of rho-kinase and hypertension. J Pharmacol Exp Ther 313: 1248-1253, 2005.
4. Cohen RA. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis 38: 105-128, 1995.
5. Eckel RH, Wassef M, Chait A, Sobel B, Barrett E, King G, Lopes-Virella M, Reusch J, Ruderman N, Steiner G, and Vlassara H. Prevention Conference VI: Diabetes and Cardiovascular Disease. Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation 105: e138-e143, 2002.
6. Fang TC and Huang WC. Angiotensin receptor blockade blunts hyperinsulinemia-induced hypertension in rats. Hypertension 32: 235-242, 1998.
7. Feener EP and King GL. Vascular dysfunction in diabetes mellitus. Lancet 350: 9-13, 1997.
8. Foukas LC, Daniele N, Ktori C, Anderson KE, Jensen J, and Shepherd PR. Direct effects of caffeine and theophylline on p110δ and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. J Biol Chem 277: 37124-37130, 2002.
9. Gans RO, Bilo HJ, von Maarschalkerweerd WW, Heine RJ, Nauta JJ, and Donker AJ. Exogenous insulin augments in healthy volunteers the cardiovascular reactivity to noradrenaline but not to angiotensin II. J Clin Invest 88: 512-518, 1991.
10. Hafizi S, Wang X, Chester AH, Yacoub MH, and Proud CG. ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells. Am J Physiol Heart Circ Physiol 287: H1232-H1238, 2004.
11. Hall JE, Brands MW, Zappe DH, and Galicia MA. Insulin resistance, hyperinsulinaemia, and hypertension: causes, consequences, or merely correlations? Proc Soc Exp Biol Med 208: 317-329, 1995.
12. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, and Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38: 884-890, 2001.
13. 1-Adrenergic receptors activate phosphatidylinositol 3-kinase in human vascular smooth muscle cells. Role in mitogenesis. J Biol Chem 271: 8977-8982, 1996.
14. Jacobsen P, Andersen S, Jensen BR, and Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 14: 992-999, 2003.
15. Jost-Vu E, Horton R, and Antonipillai I. Altered regulation of renin secretion by insulinlike growth factors and angiotensin II in diabetic rats. Diabetes 41: 1100-1105, 1992.
16. Juan CC, Chien Y, Wu LY, Yang WM, Chang CL, Lai YH, Ho PH, Kwok CF, and Ho LT. Angiotensin II enhances insulin sensitivity in vitro and in vivo. Endocrinology 146: 2246-2254, 2005.
17. Kamide K, Hori MT, Zhu JH, Barrett JD, Eggena P, and Tuck ML. Insulin-mediated growth in aortic smooth muscle and the vascular renin-angiotensin system. Hypertension 32: 482-487, 1998.
18. Kido Y, Burks DJ, Withers D, Bruning JC, Kahn CR, White MF, and Accili D. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 105: 199-205, 2000.
19. Kobayashi T and Kamata K. Effect of insulin treatment on smooth muscle contractility and endothelium-dependent relaxation in rat aortae from established STZ-induced diabetes. Br J Pharmacol 127: 835-842, 1999.
20. Kobayashi T and Kamata K. Short-term insulin treatment and aortic expressions of IGF-1 receptor and VEGF mRNA in diabetic rats. Am J Physiol Heart Circ Physiol 283: H1761-H1768, 2002.
21. Kobayashi T, Kaneda A, and Kamata K. Possible involvement of IGF-1 receptor and IGF-binding protein in insulin-induced enhancement of noradrenaline response in diabetic rat aorta. Br J Pharmacol 140: 285-294, 2003.
22. Kobayashi T, Taguchi K, Yasuhiro T, Matsumoto T, and Kamata K. Impairment of PI3-K/Akt pathway underlies attenuated endothelial function in aorta of type 2 diabetic mouse model. Hypertension 44: 956-962, 2004.
23. Koivisto VA, Stevens LK, Mattock M, Ebeling P, Muggeo M, Stephenson J, and Idzior-Walus B. Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care 19: 689-697, 1996.
24. Kurosu H, Maehama T, Okada T, Yamamoto T, Hoshino S, Fukui Y, Ui M, Hazeki O, and Katada T. Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110β is synergistically activated by the βγ-subunits of G proteins and phosphotyrosyl peptide. J Biol Chem 272: 24252-24256, 1997.
25. 2+ channels by phosphatidylinositol 3,4,5-trisphosphate. Circ Res 95: 300-307, 2004.
26. 2+ channels. Circ Res 89: 692-699, 2001.
27. Maier U, Babich A, and Nurnberg B. Roles of non-catalytic subunits in Gβγ-induced activation of class I phosphoinositide 3-kinase isoforms β and γ. J Biol Chem 274: 29311-29317, 1999.
28. Matsumoto T, Wakabayashi K, Kobayashi T, and Kamata K. Diabetes-related changes in cAMP-dependent protein kinase activity and decrease in relaxation response in rat mesenteric artery. Am J Physiol Heart Circ Physiol 287: H1064-H1071, 2004.
29. Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, Goodyear LJ, Iannacone M, Accili D, Cantley LC, and Kahn CR. Reduced expression of the murine p85α subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest 109: 141-149, 2002.
30. Navarro-Cid J, Maeso R, Perez-Vizcaino F, Cachofeiro V, Ruilope LM, Tamargo J, and Lahera V. Effects of losartan on blood pressure, metabolic alterations, and vascular reactivity in the fructose-induced hypertensive rat. Hypertension 26: 1074-1078, 1995.
31. Northcott CA, Hayflick JS, and Watts SW. PI3-kinase upregulation and involvement in spontaneous tone in arteries from DOCA-salt rats: is p110δ the culprit? Hypertension 43: 885-890, 2004.
32. Northcott CA, Poy MN, Najjar SM, and Watts SW. Phosphoinositide 3-kinase mediates enhanced spontaneous and agonist-induced contraction in aorta of deoxycorticosterone acetate-salt hypertensive rats. Circ Res 91: 360-369, 2002.
33. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L, Ellis D, and Becker DJ. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 26: 1374-1379, 2003.
34. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 75: 473-486, 1995.
35. Schernthaner G, Schwarzer C, Kuzmits R, Muller MM, Klemen U, and Freyler H. Increased angiotensin-converting enzyme activities in diabetes mellitus: analysis of diabetes type, state of metabolic control and occurrence of diabetic vascular disease. J Clin Pathol 37: 307-312, 1984.
36. Shinozaki K, Ayajiki K, Nishio Y, Sugaya T, Kashiwagi A, and Okamura T. Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension 43: 255-562, 2004.
37. Snell-Bergeon JK, Hokanson JE, Jensen L, MacKenzie T, Kinney G, Dabelea D, Eckel RH, Ehrlich J, Garg S, and Rewers M. Progression of coronary artery calcification in type 1 diabetes: the importance of glycemic control. Diabetes Care 26: 2923-2928, 2003.
38. Su X, Smolock EM, Marcel KN, and Moreland RS. Phosphatidylinositol 3-kinase modulates vascular smooth muscle contraction by calcium and myosin light chain phosphorylation-independent and -dependent pathways. Am J Physiol Heart Circ Physiol 286: H657-H666, 2004.
39. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, and Holman RR. Risk factors for coronary artery disease in non-insulin-dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316: 823-828, 1998.
40. 1-adrenergic receptor subtypes in the regulation of arterial pressure. Life Sci 57: 2291-2308, 1995.